科学研究
Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
编辑:www.4001.com  发布时间:2016-10-26  来源:  阅读次数:
Mol Cell.  2016 Oct 4. pii: S1097-2765(16)30565-2. doi: 10.1016/j.molcel.2016.09.016. [Epub ahead of print]

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor CellSurvival.

Xiao D 1,  Yue M 2,  Su H 2,  Ren P 2,  Jiang J 2,  Li F 3,  Hu Y 2,  Du H 3,  Liu H 1,  Qing G 4.

Author information

  • 1Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Medical Research Institute, Wuhan University, Wuhan 430071, China.
  • 2Medical Research Institute, Wuhan University, Wuhan 430071, China.
  • 3Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan 430072, China.
  • 4Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Medical Research Institute, Wuhan University, Wuhan 430071, China. Electronic address: qingguoliang@whu.edu.cn.

Abstract

MYCN amplification in human cancers predicts poor prognosis and resistance to therapy. However, pharmacological strategies that directly target N-Myc, the protein encoded by MYCN, remain elusive. Here, we identify a molecular mechanism responsible for reciprocal activation between Polo-like kinase-1 (PLK1) and N-Myc. PLK1 specifically binds to the SCFFbw7 ubiquitin ligase, phosphorylates it, and promotes its autopolyubiquitination and proteasomal degradation, counteracting Fbw7-mediated degradation of N-Myc and additional substrates, including cyclin E and Mcl1. Stabilized N-Myc in turn directly activates PLK1 transcription, constituting a positive feedforward regulatory loop that reinforces Myc-regulated oncogenic programs. Inhibitors of PLK1 preferentially induce potent apoptosis of MYCN-amplified tumor cells from neuroblastoma and small cell lung cancer and synergistically potentiate the therapeutic efficacies of Bcl2 antagonists. These findings reveal a PLK1-Fbw7-Myc signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with Bcl2 antagonists, as potential effective therapeutics for MYC-overexpressing cancers.

KEYWORDS:

ABT199; BI6727; Fbw7; Myc; PLK1; neuroblastoma; small cell lung carcinoma; targeted therapy; ubiquitination

PMID:  
27773673  
DOI:  
10.1016/j.molcel.2016.09.016

地 址:湖北省武汉市武昌区东湖路115号 邮政编码:430071 电 话:027-68750205  邮 箱:mri@whu.edu.cn

CopyRight© 2016  版权所踊岷澳门百老汇4001登录网站

XML 地图 | Sitemap 地图